REGN - Regeneron Pharmaceuticals, Inc.

Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - July 19, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period").

Jul 19, 2026 08:00 AM • newsfilecorp.com (Hide legal announcements)

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights -- REGN

[url="]The DJS Law Group[/url] reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASD

Jul 18, 2026 08:00 AM • gurufocus.com (Hide legal announcements)

Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN

LOS ANGELES--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN.

Jul 18, 2026 07:30 AM • businesswire.com

REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Regeneron between August 1, 2025 and May 15, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (""Regeneron" or the "Company") (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 18, 2026 02:25 AM • newsfilecorp.com (Hide legal announcements)

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

Jul 17, 2026 06:16 PM • businesswire.com (Hide legal announcements)

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Regeneron (REGN) To Contact Him Directly To Discuss Their Options

Jul 17, 2026 11:59 AM • globenewswire.com (Hide legal announcements)

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”).

Jul 17, 2026 08:28 AM • globenewswire.com (Hide legal announcements)

REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options

Jul 17, 2026 06:39 AM • globenewswire.com (Hide legal announcements)

REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.

SAN DIEGO, July 17, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026.  Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.

Jul 17, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

3 High-Yield Dividend Stocks to Buy and Hold

All three can be bought on the dip.

Jul 16, 2026 09:00 PM • fool.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi and Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, inclusive.

Jul 16, 2026 02:03 PM • globenewswire.com (Hide legal announcements)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Regeneron Pharmaceuticals, Inc. Common Stock and Sets a Lead Plaintiff Deadline of September 14, 2026

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, inclusive. You are hereby notified that the class action lawsuit Allen Cheatham v.

Jul 16, 2026 02:03 PM • globenewswire.com (Hide legal announcements)

Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $REGN #Health--Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeutics, Inc. (NASDAQ: REGN) from August 1, 2025 to May 15, 2026. Regeneron is a pharmaceutical company that discovers, invents, develops, manufactures, tests, and commercializes medicines to treat various disorders worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The.

Jul 16, 2026 11:09 AM • businesswire.com (Hide legal announcements)

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Jul 09, 2026 05:56 AM • zacks.com

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Jul 07, 2026 09:11 AM • zacks.com

Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.

Jul 07, 2026 08:30 AM • 247wallst.com

Here's Why Regeneron (REGN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jul 07, 2026 06:41 AM • zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Jul 07, 2026 05:56 AM • zacks.com

Why Regeneron (REGN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Jul 02, 2026 06:51 AM • zacks.com

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

It might pull it off, provided several things fall right in place.

Jul 01, 2026 11:45 AM • fool.com

Regeneron price target lowered to $854 from $855 at Piper Sandler

$854.00 (was $662.88)

Biren Amin · Piper Sandler

Jul 09, 2026 07:13 AM • TheFly

Regeneron price target lowered to $730 from $788 at Morgan Stanley

$730.00 (was $676.23)

Terence Flynn · Morgan Stanley

Jul 08, 2026 07:39 AM • TheFly

Regeneron price target lowered to $769 from $778 at Truist

$769.00 (was $670.54)

Truist Financial

Jul 07, 2026 09:13 AM • TheFly

Regeneron price target lowered to $800 from $990 at HSBC

$800.00 (was $643.00)

HSBC

Jul 06, 2026 10:25 AM • TheFly

Regeneron Pharma (REGN) PT Lowered to $750 at Cantor Fitzgerald on Negative Eylea OpticsMember Login

$750.00 (was $654.27)

Cantor Fitzgerald

Jul 06, 2026 06:46 AM • StreetInsider

Regeneron price target lowered to $875 from $1,057 at Canaccord

$875.00 (was $629.68)

John Newman · Canaccord Genuity

May 19, 2026 06:43 AM • TheFly

Regeneron price target lowered to $860 from $900 at Wolfe Research

$860.00 (was $629.36)

Alexandria Hammond · Wolfe Research

May 18, 2026 02:48 PM • TheFly

Regeneron price target lowered to $825 from $875 at Evercore ISI

$825.00 (was $619.84)

Evercore ISI

May 18, 2026 08:40 AM • TheFly

Regeneron price target lowered to $707 from $762 at RBC Capital

$707.00 (was $619.62)

RBC Capital

May 18, 2026 08:30 AM • TheFly

Regeneron price target lowered to $778 from $796 at Truist

$778.00 (was $619.95)

Truist Financial

May 18, 2026 08:18 AM • TheFly

Regeneron price target lowered to $730 from $900 at BMO Capital

$730.00 (was $698.25)

BMO Capital

May 18, 2026 07:37 AM • TheFly

Regeneron price target lowered to $855 from $875 at Piper Sandler

$855.00 (was $698.25)

Piper Sandler

May 18, 2026 07:17 AM • TheFly

Leerink cuts Regeneron to Market Perform on LAG-3 failure, Eylea erosion risk

$641.00 (was $698.25)

Market Perform · Leerink Partners

May 18, 2026 06:25 AM • TheFly

Regeneron price target raised to $995 from $975 at Guggenheim

$995.00 (was $707.06)

Yatin Suneja · Guggenheim

May 01, 2026 06:47 AM • TheFly

Regeneron price target lowered to $788 from $796 at Morgan Stanley

$788.00 (was $703.18)

Terence Flynn · Morgan Stanley

Apr 30, 2026 12:46 PM • TheFly

Regeneron price target lowered to $796 from $801 at Truist

$796.00 (was $692.75)

Truist Financial

Apr 30, 2026 08:01 AM • TheFly

Regeneron price target lowered to $917 from $923 at Barclays

$917.00 (was $686.36)

Barclays

Apr 30, 2026 05:41 AM • TheFly

Raymond James Reiterates Outperform Rating on Regeneron Pharma (REGN)

$910.00 (was $746.58)

Chris Raymond · Raymond James

Apr 22, 2026 02:56 PM • StreetInsider

Regeneron price target raised to $796 from $769 at Morgan Stanley

$796.00 (was $746.15)

Morgan Stanley

Apr 10, 2026 08:54 AM • TheFly

Regeneron price target lowered to $921 from $925 at Bernstein

$921.00 (was $775.53)

Bernstein

Apr 08, 2026 06:49 AM • TheFly